Imai S
Department of Virology, Cancer Institute, Hokkaido University School of Medicine, Sapporo, Japan.
Hokkaido Igaku Zasshi. 1990 Sep;65(5):481-92.
The inapparent Epstein-Barr virus (EBV) infection status in healthy Japanese subjects was assessed for their EBV seroepidemiology, oral EBV excretion, and EBV-specific cellular immunity, in comparison with immunosuppressed patients and patients with infectious mononucleosis. The seroepidemiologic data of 1,086 healthy donors indicate that EBV infects the vast majority of young children by 2-3 years of age and the viral persistence follows in nearly all adults throughout life. EBV antibody titers were significantly higher in both early and late ages. When 35 seropositive healthy persons were monthly assessed for their oral EBV excretion during 1 year period, 25% shed the virus consistently, 50% every other time, and the remaining 25% occasionally. EBV was shed more frequently from 17 immunosuppressed patients and all times from 15 cases of infectious mononucleosis, in the acute and convalescent phases and also during 1 year after healing. There was a tendency that high frequency EBV shedders had high titer EBV in the mouth. In infected healthy persons, EBV-specific killer T cells were well functioning throughout life; however, the killer T cell activity were significantly low in immunosuppressed patients. The killer T cell activity first developed in infectious mononucleosis 1 week after the onset and reached the same level as in seropositive healthy persons, by 4 weeks. These findings indicate that EBV-specific cellular immunity plays an important role in the establishment and maintenance of the inapparent EBV infection in humans.
为了研究健康日本受试者的爱泼斯坦-巴尔病毒(EBV)隐性感染状况,我们对其EBV血清流行病学、口腔EBV排泄情况以及EBV特异性细胞免疫进行了评估,并与免疫抑制患者和传染性单核细胞增多症患者进行了比较。1086名健康献血者的血清流行病学数据表明,EBV在2至3岁的绝大多数幼儿中感染,并且几乎所有成年人在一生中都会持续感染该病毒。EBV抗体滴度在早期和晚期均显著更高。在1年的时间里,每月对35名血清阳性的健康人进行口腔EBV排泄评估,25%的人持续排出病毒,50%的人每隔一次排出病毒,其余25%的人偶尔排出病毒。17名免疫抑制患者排出EBV的频率更高,15例传染性单核细胞增多症患者在急性期、恢复期以及治愈后的1年中均始终排出病毒。有高频EBV排出者口腔中EBV滴度较高的趋势。在受感染的健康人中,EBV特异性杀伤性T细胞在一生中都能正常发挥功能;然而,免疫抑制患者的杀伤性T细胞活性显著较低。杀伤性T细胞活性在传染性单核细胞增多症发病1周后开始出现,并在4周时达到与血清阳性健康人相同的水平。这些发现表明,EBV特异性细胞免疫在人类隐性EBV感染的建立和维持中起着重要作用。